Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis

References

• GOLD Executive Committee [homepage on the Internet]Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease2018 Available from: http://goldcopd.comAccessed October 25, 2018
   Google Scholar
• AdeloyeDChuaSLeeCGlobal and regional estimates of COPD prevalence: Systematic review and meta-analysisJ Glob Health20155202041526755942
   PubMed Web of Science ®Google Scholar
• WangCXuJYangLPrevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional studyLancet2018391101311706171729650248
   PubMed Web of Science ®Google Scholar
• VestboJEdwardsLDScanlonPDChanges in forced expiratory volume in 1 second over time in COPDN Engl J Med2011365131184119221991892
   PubMed Web of Science ®Google Scholar
• BarnesPJInhaled corticosteroids in COPD: a controversyRespiration2010802899520501985
   PubMed Web of Science ®Google Scholar
• GOLD Executive Committee [homepage on the Internet]Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease2017 Available from: http://goldcopd.comAccessed October 25, 2018
   Google Scholar
• SadaranganiSPEstesLLSteckelbergJMNon-anti-infective effects of antimicrobials and their clinical applications: a reviewMayo Clin Proc201590110912725440726
   PubMed Web of Science ®Google Scholar
• AltenburgJde GraaffCSvan der WerfTSBoersmaWGImmunomodulatory effects of macrolide antibiotics – part 1: biological mechanismsRespiration2011811677420733281
   PubMed Web of Science ®Google Scholar
• KudohSAzumaAYamamotoMIzumiTAndoMImprovement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycinAm J Respir Crit Care Med19981576 Pt 1182918329620913
   PubMed Web of Science ®Google Scholar
• FlorescuDFMurphyPJKalilACEffects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysisPulm Pharmacol Ther200922646747219328860
   PubMed Web of Science ®Google Scholar
• Figueiredo BdeCIbiapina CdaCThe role of macrolides in noncystic fibrosis bronchiectasisPulm Med2011201175198222292118
   PubMedGoogle Scholar
• KuseNAbeSHayashiHLong-term efficacy of macrolide treatment in idiopathic pulmonary fibrosis: a retrospective analysisSarcoidosis Vasc Diffuse Lung Dis201633324224627758989
   PubMed Web of Science ®Google Scholar
• ZhangHLTanMQiuAMTaoZWangCHAntibiotics for treatment of acute exacerbation of chronic obstructive pulmonary disease: a network meta-analysisBMC Pulm Med201717119629233130
   PubMed Web of Science ®Google Scholar
• NiWShaoXCaiXProphylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysisPLoS One2015103e012125725812085
   PubMed Web of Science ®Google Scholar
• DonathEChaudhryAHernandez-AyaLFLitLA meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmonary DiseaseRespir Med201310791385139223768735
   PubMed Web of Science ®Google Scholar
• LeeJSParkDAHongYSystematic review and meta-analysis of prophylactic antibiotics in COPD and/or chronic bronchitisInt J Tuberc Lung Dis201317215316223317949
   PubMed Web of Science ®Google Scholar
• YaoGYMaYLZhangMQGaoZCMacrolide therapy decreases chronic obstructive pulmonary disease exacerbation: a meta-analysisRespiration201386325426023817204
   PubMed Web of Science ®Google Scholar
• DjaminRSUzunSKluytmansJAJWMacrolides for Reducing Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseClin Pulm Med20162311622
   Google Scholar
• AlbertRKSchullerJLCOPD Clinical Research NetworkMacrolide antibiotics and the risk of cardiac arrhythmiasAm J Respir Crit Care Med2014189101173118024707986
   PubMed Web of Science ®Google Scholar
• HigginsJPAltmanDGGøtzschePCThe Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• WellsGSheaBO’ConnellDwebpage on the InternetThe Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies inmeta-analyses2012 Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.aspAccessed October 25, 2018
   Google Scholar
• AlbertRKConnettJBaileyWCAzithromycin for Prevention of Exacerbations of COPDN Engl J Med Overseas Ed20113658689698
   PubMed Web of Science ®Google Scholar
• BanerjeeDKhairOAHoneybourneDThe effect of oral clarithromycin on health status and sputum bacteriology in stable COPDRespir Med200599220821515715188
   PubMed Web of Science ®Google Scholar
• BerkhofFFDoornewaard-Ten HertogNEUilSMKerstjensHAvan den BergJWAzithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trialRespir Res201314112524229360
   PubMed Web of Science ®Google Scholar
• BlasiFBonardiDAlibertiSLong-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomyPulm Pharmacol Ther201023320020720025989
   PubMed Web of Science ®Google Scholar
• BrillSELawMEl-EmirEEffects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trialThorax2015701093093826179246
   PubMed Web of Science ®Google Scholar
• HeZYOuLMZhangJQEffect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary diseaseRespiration201080644545220881376
   PubMed Web of Science ®Google Scholar
• SeemungalTAWilkinsonTMHurstJRPereraWRSapsfordRJWedzichaJALong-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbationsAm J Respir Crit Care Med2008178111139114718723437
   PubMed Web of Science ®Google Scholar
• ShafuddinEMillsGDHolmesMDPoolePJMullinsPRBlackPNA double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary diseaseJ Negat Results Biomed20151411526346300
   PubMedGoogle Scholar
• SimpsonJLPowellHBainesKJThe effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trialPLoS One201498e10560925148049
   PubMed Web of Science ®Google Scholar
• SuzukiTYanaiMYamayaMErythromycin and common cold in COPDChest2001120373073311555501
   PubMed Web of Science ®Google Scholar
• UzunSDjaminRSKluytmansJAAzithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trialLancet Respir Med20142536136824746000
   PubMed Web of Science ®Google Scholar
• NaderiNAssayagDMostafavi-Pour-ManshadiSMLong-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary diseaseRespir Med201813812913629724384
   PubMed Web of Science ®Google Scholar
• ArakiNYanagiharaKMorinagaYAzithromycin inhibits nontypeable Haemophilus influenzae-induced MUC5AC expression and secretion via inhibition of activator protein-1 in human airway epithelial cellsEur J Pharmacol20106441–320921420619258
   PubMed Web of Science ®Google Scholar
• HuckleAWFaircloughLCToddIProphylactic antibiotic use in COPD and the potential anti-inflammatory activities of antibioticsRespir Care201863560961929463692
   PubMed Web of Science ®Google Scholar
• PolettiVCasoniGChilosiMZompatoriMDiffuse panbronchiolitisEur Respir J200628486287117012632
   PubMed Web of Science ®Google Scholar
• JonesPWSt. George’s Respiratory Questionnaire: MCIDCOPD200521757917136966
   PubMedGoogle Scholar
• MiravitllesMFerrerMPontAEffect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up studyThorax200459538739515115864
   PubMed Web of Science ®Google Scholar
• HanMKTayobNMurraySPredictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapyAm J Respir Crit Care Med2014189121503150824779680
   PubMed Web of Science ®Google Scholar
• WenzelRPFowlerAA3rdEdmondMBAntibiotic prevention of acute exacerbations of COPDN Engl J Med2012367434034722830464
   PubMed Web of Science ®Google Scholar
• SaimanLAnsteadMMayer-HamblettNEffect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trialJAMA2010303171707171520442386
   PubMed Web of Science ®Google Scholar
• RayWAMurrayKTHallKArbogastPGSteinCMAzithromycin and the Risk of Cardiovascular DeathN Engl J Med Overseas Ed20123662018811890
   PubMed Web of Science ®Google Scholar
• MortensenEMHalmEAPughMJAssociation of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumoniaJAMA2014311212199220824893087
   PubMed Web of Science ®Google Scholar
• SerisierDJMartinMLMcGuckinMAEffect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trialJAMA2013309121260126723532242
   PubMed Web of Science ®Google Scholar
• BalloyVDeveauxALebeauxDAzithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challengeBr J Pharmacol201417171783179424417187
   PubMed Web of Science ®Google Scholar
• SugawaraAShimaHSuekiANon-antibiotic 12-membered macrolides: design, synthesis and biological evaluation in a cigarette-smoking modelJ Antibiot201669431932626419414
   PubMed Web of Science ®Google Scholar